Oncology

Numerical simulations show the long-term success of immunotherapy is dependent on random fluctuations.

Cancer tumors are unable to grow larger than 2 millimeters unless angiogenesis is present.

Top news of the day from across the health care landscape.

Immune response that attacks tumors may significantly improve progression-free survival.

Proliferation assays are typically used to see how cancer cells respond to a drug, but this method may not be the most effective.

Top news of the day from across the health care landscape.

The small molecule drug, SI-2, found to improve cancer treatment in mouse models.

TAT-CaM could potentially have a multitude of applications, including cancer treatment.

The cost of oral cancer drugs spiked six-fold within the last 14 years.

Ability to produce epiregulin may influence cancer development.

Ability to produce epiregulin may influence cancer development.

The use of microparticles and mesenchymal stem cells has shown potential to treat prostate cancer.

Obese people found to be at greater risk for developing colon cancer.

Infertility and breast density may impact the risk of cancer.

Infertility and breast density may impact the risk of cancer.

Targeted approach may lead to improved treatments for cancer.

JAK2 could potentially cause treatment resistance in TNBC.

Prognostic model provides simple and accurate clinical description for each HCC patient.

JAK2 could potentially cause treatment resistance in TNBC.

Top news of the day from across the health care landscape.

Vitamin D deficiency has been associated with different cancer types, such as breast, lung, colon, and bladder cancers.

Cortistatin A is a natural product isolated from an Indonesian marine sponge with potent anti-angiogenic activity at low dosages.

Recent advances and updates in oncology and cancer drug development.

Top news of the day from across the health care landscape.

Chinese plant Huang-Qin compound shows promise treating cancer and liver disease.

CTLA-4 molecule on T cells offer potential therapeutic target.

Treatment costs climb with advanced-stage breast cancer compared with earlier stages.

Methotrexate and decadron could lower relapse rates of patients with acute lymphoblastic leukemia.